Home LiteratureArticle Details
PMID: 16143433 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.

Vaccine ·Vol. 24 ·No. 4 ·2006-01-23 ·Pages 435-42

Luo M, Yuan F, Liu Y, Jiang S, Song X, Jiang P, Yin X, Ding M, Deng H

Abstract

The membrane-proximal external region (MPER) of HIV-1 gp41 is recognized by all three anti-HIV antibodies 2F5, 4E10 and Z13 that were directly derived from AIDS patients and have broader anti-HIV neutralizing activities. Thus, the MPER has been the focus of anti-HIV vaccine design and development. However, it has been unsuccessful to generate anti-HIV neutralizing antibodies targeting this region. One possible reason is that the MPER-containing immunogens have failed to maintain the correct conformation of the MPER present within the HIV-1 viral gp41 protein. The porcine endogenous retrovirus (PERV) p15E protein is structurally similar to HIV-1 gp41, and it was recently reported that the p15E fragment can be expressed in soluble form and was capable of inducing neutralizing antibodies against the epitope within the MPER of PERV p15E. In the present study, we attempted to use the p15E fragment as a carrier and fused the HIV-1 gp41 MPER with the p15E fragment. The vesicular stomatitis virus (VSV) recombinants expressing the fusion proteins (HIV-1 gp41 MPER-p15E) were prepared as primary immunogens, and the soluble fusion protein purified from a baculovirus expression system as booster immunogens. Our results showed that the antisera obtained from immunized rabbits specifically recognized the MPER determinant presented in the gp41 fragment. Importantly, we found that the antisera had neutralizing activities against HIV-1 viruses containing HIV-1 HXB2 and JRFL envelope glycoproteins. These results offer a new strategy for HIV-1 vaccine design and development targeting the gp41 MPER.

MeSH Terms
AIDS Vaccines/administration & dosage,immunology Animals Cell Culture Techniques Gammaretrovirus/genetics,immunology HIV Antibodies/biosynthesis,immunology HIV Envelope Protein gp41/administration & dosage,chemistry,genetics,immunology HIV Infections/immunology,prevention & control HIV-1/immunology Humans Immunization Neutralization Tests Recombinant Proteins/genetics,immunology,metabolism Spodoptera
Chemicals
AIDS Vaccines HIV Antibodies HIV Envelope Protein gp41 Recombinant Proteins
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Luo Min
Department of Cell Biology and Genetics, The College of Life Sciences, No. 5 Yi He Yuan Road, Peking University, Beijing 100871, China.
Yuan Fei
Liu Yanxia
Jiang Siming
Song Xijun
Jiang Pengfei
Yin Xiaolei
Ding Mingxiao
Deng Hongkui
Article Info
Journal
Vaccine
Abbr.
Vaccine
ISSN
0264-410X
Published
2006-01-23
Epub
2005-00-18
Pages
435-42
Language
English
Region
Netherlands
NLM ID
8406899
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com